Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Has Average Price Target of $10.50

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.50.

A number of research firms have recently weighed in on CATX. William Blair began coverage on shares of Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating on the stock. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $14.00 to $4.00 in a report on Monday, October 26th. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a research report on Friday. Piper Sandler dropped their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $0.88 on Friday. Perspective Therapeutics has a 12-month low of $0.88 and a 12-month high of $6.16. The firm’s 50 day simple moving average is $2.48 and its two-hundred day simple moving average is $3.51.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. Sell-side analysts anticipate that Perspective Therapeutics will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of the business. Abel Hall LLC purchased a new stake in Perspective Therapeutics in the 1st quarter worth $49,000. Provenance Wealth Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth about $44,000. Auctus Advisors LLC increased its stake in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after purchasing an additional 17,015 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its position in shares of Perspective Therapeutics by 30.3% during the 3rd quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new position in shares of Perspective Therapeutics during the 1st quarter worth about $273,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.